)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vor Biopharma
Vor Biopharma (VOR) investor relations material
Vor Biopharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
UPSTREAM MG Phase 3 enrollment is complete; topline data are expected in H1 2027, with ocular MG and Sjögren’s disease programs advancing.
Cash, cash equivalents and marketable securities totaled $481.6M at Sept. 30, 2026, and are projected to fund operations into early 2029.
Q3 net loss was $86.7M vs. $812.7M in Q3 2025, primarily reflecting a smaller warrant-liability fair-value expense.
Financial highlights
Q3 2026 R&D expense was $34.5M vs. $14.1M in Q3 2025; G&A was $23.9M vs. $14.0M.
Q3 total operating expenses and operating loss were each $58.4M; 9M totals were each $141.5M.
9M 2026 net loss was $369.1M vs. $2,418.8M in 9M 2025; 9M R&D fell $224.3M, mainly because 2025 included a $222.6M telitacicept license-acquisition charge.
Revenue remained $0; no product-sale revenue is expected in the near term, if ever.
Outlook and guidance
UPSTREAM MG topline data are anticipated in H1 2027; UPSTREAM OMG enrollment and first patient dosing are anticipated in H1 2027.
Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital needs into early 2029, based on the current operating plan and assumptions that may change.
R&D expenses are expected to increase significantly as clinical programs advance; G&A costs are also expected to rise with development needs and public-company compliance.
Additional capital will be needed; potential sources include equity, debt, grants, collaborations or strategic transactions, with dilution and other financing risks.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vor Biopharma
- Dual BAFF/APRIL inhibition offers rapid, durable efficacy and strong market potential in MG.VOR
Stifel 2026 Virtual Immunology and Inflammation Forum - Phase III trials for Telitacicept in MG and Sjögren's show strong progress and market potential.VORCitigroup’s Biopharma Back to School Summit 2026
- Phase III MG trial enrollment completed; telitacicept aims for robust, durable, and broad efficacy.VORWells Fargo 21st Annual Healthcare Conference
- Telitacicept delivers leading efficacy and safety in autoimmune diseases, supporting global growth.VORCorporate presentation
- Net loss narrowed to $62.8M in Q2 2026, cash runway extends to 2029, key trials advance.VORQ2 2026
- Late-stage telitacicept trials target major autoimmune markets with strong efficacy and growth potential.VORJefferies Global Healthcare Conference 2026
- Q1 2026 net loss was $219.6M; cash runway extends into early 2029 as Phase 3 trials progress.VORQ1 2026
- Biotech registers 5.3M shares for resale after $75M private placement to fund autoimmune drug trials.VORRegistration filing
- Telitacicept advances in global Phase 3 trials for MG and Sjögren's, showing strong efficacy and safety.VOR44th Annual J.P. Morgan Healthcare Conference
Next Vor Biopharma earnings date
Q4 202619 Mar, 2027
Vor Biopharma
Next Vor Biopharma earnings date
Q4 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for blood cancers. The company's approach combines cell and genome engineering to create therapies that target and treat hematological malignancies. Vor's proprietary platform primarily involves engineering hematopoietic stem cells (HSCs) to enhance their compatibility with targeted therapies. The lead product candidate, an engineered HSC known as tremtelectogene empogeditemcel (trem-cel), is currently in clinical trials for the treatment of acute myeloid leukemia (AML). Vor is also working on additional therapies that involve chimeric antigen receptor T-cells (CAR-T) and antibody-drug conjugates to further expand its cancer treatment portfolio. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.